Clinical Trial Update: Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating oral Setanaxib (GKT137831) in patients with type 2 diabetes mellitus and diabetic nephropathy has completed, with results posted detail…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Type 2 Diabetes Mellitus

Drugs mentioned

• Setanaxib (GKT137831)

Snippet

Sponsor: Calliditas Therapeutics AB | Conditions: Type 2 Diabetes Mellitus With Diabetic Nephropathy | Phase 2 | Status: COMPLETED | Results posted: 2025-02-28